The FDA-Approved Drug Pyrvinium Selectively Targets ER<sup>+</sup> Breast Cancer Cells with High INPP4B Expression

The FDA-Approved Drug Pyrvinium Selectively Targets ER<sup>+</sup> Breast Cancer Cells with High INPP4B Expression

The majority of breast cancers are estrogen receptor-positive (ER<sup>+</sup>), and endocrine therapies that suppress ER signaling are the standard-of-care treatment for this subset. However, up to half of all ER<sup>+</sup> cancers eventually relapse, highlighting a need for...

Full description

Bibliographic Details
Main Authors: Samuel J. Rodgers, Lisa M. Ooms, Christina A. Mitchell
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
breast cancer
ER
INPP4B
pyrvinium
tamoxifen
Online Access:https://www.mdpi.com/2072-6694/15/1/135

Internet

https://www.mdpi.com/2072-6694/15/1/135

Similar Items